News

24 March 2022

Investing in TB prevention strategies with Long-Acting injectables

1 December 2021

World AIDS Day: Are long-acting HIV therapies the future?

7 October 2021

AGILE COVID-19 drug testing platform opens new trial in South Africa

21 September 2021

Tandem Nano secures licence agreement for long-acting technologies for malaria, tuberculosis, and hepatitis C

25 May 2021

New Unilever Radiochemistry Research Fellow

18 May 2021

The Nanotherapeutics Hub joins iiCON

14 April 2021

Long-acting injectable medicine as potential route to COVID-19 therapy

12 January 2021

Two new therapies to be tested in ground-breaking COVID-19 clinical trial

12 January 2021

Liverpool launches new Centre of Excellence for Long-acting Therapeutics

15 October 2020

Study highlights risks associated with the sequential infection of influenza followed by COVID-19

19 June 2020

£2.2m for Liverpool-led initiative to rapidly identify COVID-19 ‘game changing’ drugs

27 April 2020

University scientists receive free support to ensure ‘timely dissemination’ of COVID-19 research findings

28 March 2020

University launches new emergency fundraising campaign to help fight against COVID-19

31 January 2020

£24m boost for revolutionary long-acting medicine research

3 June 2019

Double success for innovative ‘child-friendly’ HIV treatment

24 January 2019

£750k boost for the development of Nano-materials

27 March 2018

£3m boost for Liverpool advanced materials and healthcare research

22 January 2018

New long-acting approach for malaria prophylaxis developed

15 September 2017

£2.2m collaboration to develop new approaches for HIV therapy

13 April 2017

New episodes of our podcast now available